Skip to main content
SpringerLink
Log in
Book cover

Lymphoma pp 257–266Cite as

AIDS-Related Lymphoma

  • Chapter
  • First Online:

Part of the book series: Current Clinical Oncology ((CCO,volume 43))

Abstract

Patients infected with human immunodeficiency virus (HIV) are at greater risk of developing non-Hodgkin lymphoma (NHL) than the general population. As highly active antiretroviral therapy became available, the survival of many NHL patients has become comparable to that of HIV-negative patients. In addition, Hodgkin lymphoma (HL) has become one of the most common cancers in this population. HIV-HL is a different entity from HL in HIV-negative subjects with a poorer prognosis that is associated with tumor subtype, Epstein-Barr virus (EBV) infection, and “B” symptoms.

This review considers the prognostic factors and new approaches to the treatment of patients with AIDS-related NHL and HL. Both developments can also be attributed to new treatment strategies, such as the use of effective infusional regimens, rituximab combinations, and also high-dose therapy with autologous stem cell transplantation. Functional imaging such as positron emission tomography and computed tomography (FDG-PET) may help guide treatment strategy and minimize long-term toxicity. However, unresolved issues persist, such as the optimal therapy for patients with Burkitt ARL or central nervous system involvement.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bohlius J, Schmidlin K, Boue F, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood. 2011;117(23):6100–8.

    Article  PubMed  CAS  Google Scholar 

  2. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112:4384–99.

    Article  PubMed  CAS  Google Scholar 

  3. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10:1152–9.

    Article  PubMed  CAS  Google Scholar 

  4. Gerard L, Meignin V, Galicier L, et al. Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication. AIDS. 2009;23:2301–8.

    Article  PubMed  Google Scholar 

  5. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28:773–9.

    Article  PubMed  CAS  Google Scholar 

  6. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430–8.

    Article  PubMed  CAS  Google Scholar 

  7. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107:3832–40.

    Article  PubMed  CAS  Google Scholar 

  8. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105:1891–7.

    Article  PubMed  CAS  Google Scholar 

  9. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47.

    Article  PubMed  Google Scholar 

  10. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115:3017–24.

    Article  PubMed  CAS  Google Scholar 

  11. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-­associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23:4372–80.

    Article  PubMed  Google Scholar 

  12. Castillo JJ, Beltran BE, Bibas M, et al. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. Am J Hematol. 2011;86:256–61.

    Article  PubMed  Google Scholar 

  13. Girard T, Luquet-Besson I, Baran-Marszak F, Raphael M, Boue F. HIV+ MALT lymphoma remission induced by highly active antiretroviral therapy alone. Eur J Haematol. 2005;74:70–2.

    Article  PubMed  Google Scholar 

  14. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Article  PubMed  CAS  Google Scholar 

  15. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:4123–8.

    Article  PubMed  CAS  Google Scholar 

  16. Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140:411–9.

    Article  PubMed  CAS  Google Scholar 

  17. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538–43.

    Article  PubMed  CAS  Google Scholar 

  18. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008–16.

    Article  PubMed  CAS  Google Scholar 

  19. Mounier N, Spina M, Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol. 2007;136:685–98.

    Article  PubMed  CAS  Google Scholar 

  20. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653–9.

    Article  PubMed  CAS  Google Scholar 

  21. Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood. 2007;110:2846–54.

    Article  PubMed  CAS  Google Scholar 

  22. Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma. AIDS. 2010;24:851–6.

    Article  PubMed  CAS  Google Scholar 

  23. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008;113:117–25.

    Article  PubMed  CAS  Google Scholar 

  24. Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immuno­deficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51:2047–53.

    Article  PubMed  Google Scholar 

  25. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003;21:4423–7.

    Article  PubMed  CAS  Google Scholar 

  26. Diez-Martin JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113:6011–4.

    Article  PubMed  CAS  Google Scholar 

  27. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003;21:3447–53.

    Article  PubMed  Google Scholar 

  28. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20:1645–54.

    Article  PubMed  Google Scholar 

  29. Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS. 2002;16:531–6.

    Article  PubMed  CAS  Google Scholar 

  30. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immuno­deficiency in persons with HIV/AIDS. Blood. 2006;108:3786–91.

    Article  PubMed  CAS  Google Scholar 

  31. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin’s disease derives from post-germinal center B cells. Blood. 1999;93:2319–26.

    PubMed  CAS  Google Scholar 

  32. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007;38:1293–304.

    Article  PubMed  CAS  Google Scholar 

  33. Vaccher E, Spina M, Tirelli U. Clinical aspects and management of Hodgkin’s disease and other tumours in HIV-infected individuals. Eur J Cancer. 2001;37:1306–15.

    Article  PubMed  CAS  Google Scholar 

  34. Spina M, Berretta M, Tirelli U. Hodgkin’s disease in HIV. Hematol Oncol Clin North Am. 2003;17:843–58.

    Article  PubMed  Google Scholar 

  35. Gisselbrecht C, Mounier N, Andre M, et al. How to define intermediate stage in Hodgkin’s lymphoma? Eur J Haematol Suppl. 2005;66:111–4.

    Article  PubMed  Google Scholar 

  36. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–14.

    Article  PubMed  CAS  Google Scholar 

  37. Spina M, Ribera J, Gabarre J, et al. Hodgkin’s disease and HIV infection: prognostic factors in 596 patients within the European group for the study of HIV and tumours (GECAT). 8th international symposium on Hodgkin Lymphoma. Cologne 23–26 Oct 2010. Hematologica. 2010;95:23C060.

    Google Scholar 

  38. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol. 2004;125:455–62.

    Article  PubMed  Google Scholar 

  39. Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica. 2007;92:191–8.

    Article  PubMed  CAS  Google Scholar 

  40. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100:1984–8.

    Article  PubMed  CAS  Google Scholar 

  41. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol. 2003;14:1562–9.

    Article  PubMed  CAS  Google Scholar 

  42. Spina M, Rossi G, Antinori A, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV) Abst 227. Ann Oncol. 2008;19:152.

    Article  Google Scholar 

  43. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP. Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Crit Rev Oncol Hematol. 2009;72:10–20.

    Article  PubMed  Google Scholar 

  44. Just PA, Fieschi C, Baillet G, Galicier L, Oksenhendler E, Moretti JL. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS. 2008;22:695–700.

    Article  PubMed  Google Scholar 

  45. Goshen E, Davidson T, Avigdor A, Zwas TS, Levy I. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med. 2008;33:610–4.

    Article  PubMed  Google Scholar 

  46. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50:1–4.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Onco-Haematology, Archet Hospital, Route de Saint Antoine Ginestiere, Nice, 06200, France

    Nicolas Mounier MD, PhD

  2. Department of Medical Oncology A, National Cancer Institute, Via Franco Gallini, Aviano, 33081, Italy

    Michele Spina MD

Authors
  1. Nicolas Mounier MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michele Spina MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolas Mounier MD, PhD .

Editor information

Editors and Affiliations

  1. Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Anas Younes

  2. Service d'Hematologie, CHU Lyon-Sud, chemin du Grand Revoyet, Pierre Bénite, 69310, France

    Bertrand Coiffier

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Mounier, N., Spina, M. (2013). AIDS-Related Lymphoma. In: Younes, A., Coiffier, B. (eds) Lymphoma. Current Clinical Oncology, vol 43. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-408-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-408-1_16

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-407-4

  • Online ISBN: 978-1-62703-408-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation